Browse all 652 ETFs by category, no search needed
Global 184
US market 64
Country 92
Core UCITS 16
Sector 103
Style & factor 111
Theme 45
Dividend 37
Global X Genomics & Biotechnology ETF (GNOM)
Look-through valuation · Sector · Expense ratio 0.50 % · ISIN US37954Y4347
Price history (since 2019)
Monthly close since 2019. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Twist Bioscience Corp TWST | 6.1 % | n/a | n/a |
| Guardant Health Inc GH | 5.9 % | n/a | n/a |
| 10X Genomics Inc TXG | 5.6 % | −70.3 % | 65 |
| Natera Inc NTRA | 4.8 % | −95.0 % | 37 |
| Illumina Inc ILMN | 4.8 % | −50.5 % | 83 |
| Biomarin Pharmaceutical Inc BMRN | 4.1 % | −43.5 % | 67 |
| Bio-Techne Corp TECH | 4.0 % | −87.1 % | 67 |
| Vertex Pharmaceuticals Inc VRTX | 3.9 % | −47.0 % | 79 |
| Arrowhead Pharmaceuticals Inc ARWR | 3.9 % | −89.4 % | 51 |
| Praxis Precision Medicines Inc PRAX | 3.5 % | n/a | n/a |
| Moderna Inc MRNA | 3.5 % | −79.9 % | 45 |
| Qiagen NV QGEN | 3.4 % | −9.5 % | 78 |
| Crispr Therapeutics AG CRSP | 3.1 % | −69.1 % | 30 |
| Veracyte Inc VCYT | 3.0 % | −59.1 % | 71 |
| Genscript Biotech Corp 1548 | 3.0 % | −41.7 % | 55 |
| BioNTech SE BNTX | 2.8 % | −50.8 % | 53 |
| Legend Biotech Corp LEGN | 2.7 % | n/a | n/a |
| Caris Life Sciences, Inc. Common Stock CAI | 2.3 % | −84.0 % | 47 |
| Ultragenyx RARE | 2.1 % | −10.9 % | 36 |
| Eli Lilly and Company LLY | 2.1 % | −68.1 % | 69 |
| Beam Therapeutics Inc BEAM | 2.1 % | n/a | n/a |
| Uniqure NV QURE | 2.1 % | n/a | n/a |
| CareDx Inc CDNA | 1.8 % | −79.2 % | 68 |
| GeneDx Holdings Corp. WGS | 1.8 % | −94.2 % | 51 |
| Gilead Sciences Inc GILD | 1.6 % | +7.8 % | 83 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 49 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +71.9 % below FV
- 2 FXI iShares China Large-Cap ETF +53.7 % below FV
- 3 CHIQ Global X MSCI China Consumer Disc ETF +48.5 % below FV
- 4 FLCH Franklin FTSE China ETF +36.0 % below FV
- 5 KWEB KraneShares CSI China Internet ETF +33.5 % below FV
- 6 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +32.5 % below FV
- 7 MCHI iShares MSCI China ETF +28.0 % below FV
- 8 ITB iShares U.S. Home Construction ETF +13.7 % below FV
- 9 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +12.7 % below FV
- 10 TAN Invesco Solar ETF +10.8 % below FV
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Global X Genomics & Biotechnology ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Aug 14, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.